According to our nutritional examinations, increased
cholesterol intake may be one of the main causes of
an increase in the prevalence of NAFLD. Therefore,
as a potential treatment, cholesterol-lowering agents
look promising. Indeed, several recent studies endorse
the clinical indication of statin therapy for NAFLD.
Ezetimibe has recently been viewed as an alternative
to statin therapy in patients with hypercholesterolemia.
Ezetimibe targets the cholesterol absorption/reabsorption
step, and accordingly ezetimibe may be a suitable
treatment for NAFLD. Larger trials are needed to confirm
whether ezetimibe or statins are really efficacious as
monotherapeutic agents and, to maximize clinical benefits
while minimizing side effects, further trials may be
required to investigate the best combination partners for
the treatment of NAFLD.

根据我们的营养研究，增加胆固醇的摄入量可能是NAFLD（非酒精性脂肪肝）患病率增加的主要原因之一。因此作为一个有可能的治疗方案，降低胆固醇的药是有前景的。事实上，几个最近的研究赞同斯达汀（一种抑制素）药物疗法治疗NAFLD的临床适应症。依泽替米贝（降血脂药）最近被视为抑制素疗法的替代品去治疗血脂胆醇过多的病人。依泽替米贝作用于胆固醇吸收和再吸收的过程，相应的依泽替米贝可能适用于治疗NAFLD。大量的实验被需要来确定依泽替米贝或者斯达汀作为唯一的治疗法是否真的有效，去最大化临床效应同时减小副作用，进一步的实验可能需要去调查治疗NAFLD的最佳组合。